Kenvue (NYSE:KVUE) Releases Earnings Results, Hits Estimates

Kenvue (NYSE:KVUE) announced its earnings results on Thursday. The company reported $0.26 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.26, Zacks reports. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Kenvue updated its FY 2025 guidance to 1.440-1.469 EPS.

Kenvue Trading Up 2.2 %

Shares of NYSE:KVUE opened at $20.23 on Friday. The business has a 50 day moving average of $21.61 and a 200-day moving average of $21.93. The stock has a market cap of $38.79 billion, a PE ratio of 38.17, a P/E/G ratio of 2.16 and a beta of 1.45. Kenvue has a 12-month low of $17.67 and a 12-month high of $24.46. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66.

Kenvue Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th will be paid a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a dividend yield of 4.05%. The ex-dividend date is Wednesday, February 12th. Kenvue’s dividend payout ratio is presently 154.72%.

Analysts Set New Price Targets

KVUE has been the topic of a number of recent research reports. Bank of America lifted their price objective on shares of Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a report on Tuesday, October 22nd. Citigroup lowered their price target on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 15th. Canaccord Genuity Group decreased their price objective on Kenvue from $27.00 to $24.00 and set a “buy” rating for the company in a report on Friday. JPMorgan Chase & Co. lifted their target price on Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. Finally, Piper Sandler raised Kenvue from a “neutral” rating to an “overweight” rating and increased their price target for the company from $21.00 to $26.00 in a research report on Monday, January 6th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, Kenvue currently has an average rating of “Hold” and a consensus target price of $23.00.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.